(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 July 2017 (13.07.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/118700 A1

(51) International Patent Classification:
A61K 47/50 (2017.01)

(21) International Application Number:
PCT/EP2017/050213

(22) International Filing Date:
5 January 2017 (05.01.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

16150628.2	8 January 2016 (08.01.2016)	EP
16179289.0	13 July 2016 (13.07.2016)	EP
16191461.9	29 September 2016 (29.09.2016)	EP

(71) Applicant: **ASCENDIS PHARMA GROWTH DISORDERS A/S** [DK/DK]; Tuborg Boulevard 5, 2900 Hellerup (DK).

(72) Inventors: **SPROGØE, Kennett**; Vængestien 7, 2840 Holte (DK). **RAU, Harald**; Talstraße 41i, 69221 Dossenheim (DE). **BERNHARD, Ana**; Rohrbacher Str. 72, 69115 Heidelberg (DE). **HERSEL, Ulrich**; Fritz-Frey-Strasse 8, 69121 Heidelberg (DE). **CLEEMANN, Felix**; Adam-Karrillon-Str. 58, 55118 Mainz (DE). **WEGGE, Thomas**; Kurfürstenanlage 45, 69115 Heidelberg (DE).

(74) Agent: **BÜCHEL, Edwin**; Isenbruck Bösl Hörschler LLP Patentanwälte, EASTSITE ONE, Seckenheimer Landstraße 4, 68163 Mannheim (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2017/118700 A1

(54) **Title**: CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY

(57) **Abstract**: The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an *in vitro* NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.